Cipla Launches Generic Saxenda in US as GLP-1 Competition Intensifies
Cipla has launched a generic Saxenda (liraglutide) in the U.S., crediting Orbicular’s FDA approval, a move with supply and sourcing implications for the GLP-1 peptide market.
Neuland Names Saharsh Davuluri CEO as $30M Hyderabad Peptide Plant Targets Mid-2026
Neuland appointed Saharsh Davuluri CEO to lead an aggressive peptide expansion, with a $30M Hyderabad facility and a 6.37 kL first module due by mid-2026.